If you have been reading about MC1R and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
== Academic and professional career == From 1995 to 1997, Mezzenga worked as a research assistant at CERN, in collaboration with NASA (NASA Space Shuttle Discovery mission STS91). He then served as a research assistant at EPFL from 1997 to 2001. Following the completion of his PhD, he was a postdoctoral fellow at the University of California, Santa Barbara (2001–2002), where he studied self-assembly phenomena in polymer and colloidal systems. In 2003, Mezzenga joined the Nestlé Research Center in Lausanne as a senior scientist in polymers and colloids physics. From 2005 to 2009, he held a joint appointment as associate professor of physics at the University of Fribourg and researcher at the Nestlé Research Center. In 2009, Mezzenga was appointed Full Professor at ETH Zurich where he founded, and continues to lead since, the Laboratory of Food and Soft Materials. Mezzenga has held visiting professorships at several institutions, including Aalto University (formerly Helsinki University of Technology), Monash University, RMIT University, Nanyang Technological University, the University of Cagliari, Sapienza University of Rome, and Indian Institute of Technology Kharagpur.
==== As plaintiff ==== Monster Beverage Corporation has been criticized for its policy of indiscriminately suing companies and/or brands that use the word monster, the letter M, or the word beast in their marketing for trademark infringement, despite such trademarks being generally dissimilar or distinguishable from Monster's. The words monster and beast have existed in the English language since the 13th century, with the Latin letter M tracing back to the 7th century BC. By 2019, the company has initiated over a thousand trademark cases that have been reviewed by the US court system or US Patent and Trademark Office's (USPTO) Trademark Trial and Appeal Board, making them a poster child for "trademark bullying" which the USPTO defines as "a trademark owner that uses its trademark rights to harass and intimidate another business beyond what the law might be reasonably interpreted to allow." Examples of such lawsuits include the 2009 ones against Bevreview.com, a beverage review site that published an unfavorable review of the Monster Energy drink, Rock Art Brewery from Vermont that marketed a beer named "Vermonster", and the aquarium hobbyist site MonsterFishKeepers.com in 2012. The "Vermonster" case was even brought up by Senator Patrick Leahy in a study of problematic trademark litigation tactics. Monster Beverage dropped the lawsuit against the microbrewery due to the adverse publicity the lawsuit generated. In a four year case from 2015 to 2019, Monster sued Maple Leaf Sports & Entertainment (MLSE), the parent of the Toronto Raptors, and the NBA.
=== United States (1804) === On 29 April 1804, Alexander von Humboldt, accompanied by Bonpland and Monttfar, embarked from Havana on the Spanish frigate Concepcion en route to Philadelphia. They endured a week-long storm in the Bahama Straits, raising concerns for the safety of their scientific collections. After 24 days, they reached the calm waters of Delaware, where they had their first views of the United States. The landscape featured low, forest-covered shores punctuated with marshland, and as they neared Philadelphia, attractive farmhouses came into sight amidst the forest clearings. However, upon closer approach, the waterfront revealed an unsightly scene of wooden warehouses and refuse. Behind this façade lay a well-organized city of 75,000 residents, reminiscent of European towns. Its cobblestone streets lined with poplar trees, elegant three-storey red-brick houses, and well-furnished interiors stood in stark contrast to the initial impression. The main public building, aside from the State House, was Philosophic Hall, home to the American Philosophical Society, which played a crucial role in arranging for Humboldt's visit. Despite Philadelphia losing its capital status to Washington, it remained the cultural and scientific heart of the burgeoning republic. Humboldt and his companions were accommodated in an inn near the harbor on Market Street, and their arrival was promptly covered in the local newspapers.
Barbara Seliger Larsen is a mass spectrometrist, with a career in instrumentations and applications of mass spectrometry in industry, and served on the board of the American Society for Mass Spectrometry for several terms.
=== Retail editions === Half-Life 2 was simultaneously released through Steam, CD, and on DVD in several editions. Customers could order three versions: the" bronze" version includes only Half-Life 2 and Counter-Strike: Source, whereas the "silver" and "gold" editions also include Half-Life: Source and Day of Defeat: Source (ports of the original Half-Life and the Day of Defeat mod to the new engine). The "Gold Edition" additionally includes merchandise, such as a baseball cap, a strategy guide and a CD containing the soundtrack. The boxed retail copies come as standard and collector's editions. The collector's edition includes a T-shirt and sample of the Prima strategy guide. Both the disc and Steam versions require Steam to be installed and active for play to occur. None of the 2004 releases came with an instruction manual, though a reference card was included to guide people through installation and setup. In September 2005, Electronic Arts distributed a "Game of the Year Edition" of Half-Life 2, including Half-Life: Source.
Sources: en.wikipedia.org
While transformed, he wields the D-Sword Vega (ディーソード・ベガ, Dī Sōdo Bega), which possesses a gun function and allows him to perform the Vega Tornado Slash (ベガトルネードスラッシュ, Bega Torunēdo Surasshu) attack and the Vega Slash (ベガスラッシュ, Bega Surasshu) finisher. He also rides the S.P.D. Helicopter (S.P.D.ヘリコプター, Esu Pī Dī Herikoputā). Doggie Kruger is voiced by Tetsu Inada (稲田 徹, Inada Tetsu).
Somalia was likely one of the first lands to be settled by early humans due to its location. Hunter-gatherers who would later migrate out of Africa likely settled here before their migrations. During the Stone Age, the Doian and Hargeisan cultures flourished here. The oldest evidence of burial customs in the Horn of Africa comes from cemeteries in Somalia dating back to the 4th millennium BC. The stone implements from the Jalelo site in the north were also characterised in 1909 as important artefacts demonstrating the archaeological universality during the Paleolithic between the East and the West. According to linguists, the first Afroasiatic-speaking populations arrived in the region during the ensuing Neolithic period from the family's proposed urheimat ("original homeland") in the Nile Valley, or the Near East. The Laas Geel complex on the outskirts of Hargeisa in northwestern Somalia dates back approximately 5,000 years, and has rock art depicting both wild animals and decorated cows. Other cave paintings are found in the northern Dhambalin region, which feature one of the earliest known depictions of a hunter on horseback. The rock art is dated to 1,000 to 3,000 BC. Additionally, between the towns of Las Khorey and El Ayo in northern Somalia lies Karinhegane, the site of numerous cave paintings, which collectively have been estimated to be around 2,500 years old. The camel is believed to have been domesticated in the Horn region between the 2nd and 3rd millennium BC. From there, it spread to Egypt and the Maghreb.
American Brugmansia and Datura Society, Inc. (ABADS) is designated in the 2004 edition of the International Code of Nomenclature for Cultivated Plants as the official International Cultivar Registration Authority for Datura. This role was delegated to ABADS by the International Society for Horticultural Science in 2002.
== Gene and transcription == Obestatin is encoded by the same gene that encodes ghrelin, a peptide hormone. The mRNA produced from the GHRL gene has four exons. Five products of similar structure and function arise: the first is the 117-amino acid preproghrelin. (It is homologous to promotilin; both are members of the motilin family). It is cleaved to produce proghrelin which is cleaved to produce a 28-amino acid ghrelin (unacylated) and C-ghrelin(acylated). Obestatin is presumed to be cleaved from C-ghrelin.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.